How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

MO

XETRA:MorphoSys
Get a brief AI stock analysisSaves ~ 15 minutes of your time

MO

MorphoSys AGXETRA MorphoSys Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XETR - Xetra

FAIR VALUE

Is MOR undervalued compared to its fair value?

The fair value of MOR stock is hidden EUR. Relative to the market price of 67.65 EUR MorphoSys AG is hidden.

MorphoSys AG operates as a commercial-stage biopharmaceutical company. The company is headquartered in Planegg, Bayern and currently employs 629 full-time employees. The firm discovers, develops, and delivers cancer med...[More about valuation]

MorphoSys AG Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

2.777 $B

Price:

67.65 EUR

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-8.373

FINANCIALS

MorphoSys AG financial for reporting period

Income Statement

0.028 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.26 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.31 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.028 B 100%
0.025 B 90%
-0.26 B -959%
-0.31 B -1144%

Balance Sheet

1.8 B
-0.26 B


Financial Position Analysis

Assets

1.8 B
Current Assets
0.68 B
Total non-current assets
1.2 B

Total current liabilities
0.49 B
Total non-current liabilities
1.6 B

Cash Flow Statement

-0.075 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.074 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

MorphoSys AG fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-41 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-23 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is MOR attractive for investment based on fundamental analysis?

MOR stock rating is hidden. MorphoSys AG is a hidden by Eyestock methodology.

Get MOR Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-226

Gross Margin:

84

CFO / Debt ratio:

hidden

Current ratio:

2.524

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

MOR.DE analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for MOR.DE to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

MorphoSys AG competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

MorphoSys AG dividends

MOR.DE dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About MOR.DE stock

About the company MorphoSys AG

Market cap $B

2.777

Dividend yield

Shares outstanding

34.16592 B

MorphoSys AG operates as a commercial-stage biopharmaceutical company. The company is headquartered in Planegg, Bayern and currently employs 629 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

MOR.DE profile

  • Ticker

    MOR.DE

  • Country

    Germany

  • Exchange

    XETR - Xetra

  • Report currency

    EUR - Euro

  • IPO date

    09 March 1999

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    629

  • City

    Planegg

  • Address

    Semmelweisstr. 7

  • Cusip

    D55040105